Physician profile
Camille Johnson
NPI 1457732711
$6,208.25
in general payments reported to CMS, 2019-2025
47 companies · $3,772 in 2025
The $3,772 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2022: $297 · 2023: $246 · 2024: $1,657 · 2025: $3,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,768 · Long Term Medical Supply Or Device Loan: $1,863 · Education: $44.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,767.53 |
| Long Term Medical Supply Or Device Loan | $1,863.04 |
| Education | $44.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,103.12 | 2022-2025 | |
| Janssen Biotech, INC. | $411.65 | 2021-2025 | Rybrevant, Erleada, Tecvayli |
| Incyte Corporation | $292.43 | 2023-2025 | Monjuvi, Jakafi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $250.46 | 2023-2025 | Lynparza, Calquence, Enhertu |
| Puma Biotechnology, INC. | $225.20 | 2022-2024 | |
| Pfizer INC. | $219.51 | 2023-2025 | |
| Abbvie INC. | $184.32 | 2025 | |
| Celgene Corporation | $167.98 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Lilly USA, LLC | $149.15 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $146.75 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Seagen INC. | $145.73 | 2022 | |
| Adc Therapeutics America, INC. | $127.49 | 2023-2025 | |
| Daiichi Sankyo INC. | $126.66 | 2023-2025 | Enhertu, Vanflyta |
| E.R. Squibb & Sons, L.L.C. | $126.64 | 2023-2025 | Opdivo |
| Genmab U.S., INC. | $124.99 | 2025 | Epkinly |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $121.41 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Dendreon Pharmaceuticals LLC | $101.55 | 2024-2025 | Provenge |
| Sobi, INC | $90.70 | 2025 | |
| Genzyme Corporation | $89.40 | 2025 | |
| Astellas Pharma US INC | $76.77 | 2024-2025 | Vyloy |
| Emd Serono, INC. | $74.75 | 2025 | |
| Gilead Sciences, INC. | $72.16 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $70.62 | 2025 | Lynozyfic, Libtayo |
| Pharmaessentia USA Corporation | $64.31 | 2024-2025 | Besremi |
| Stemline Therapeutics INC. | $60.82 | 2025 | Orserdu |
| Eisai INC. | $56.20 | 2024-2025 | |
| Tempus Ai, INC | $49.13 | 2024 | |
| Array Biopharma INC | $41.75 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Glaxosmithkline, LLC. | $36.42 | 2025 | Jemperli |
| Rigel Pharmaceuticals, INC. | $29.78 | 2025 | Gavreto, Rezlidhia, Tavalisse |
| Amgen INC. | $29.64 | 2025 | Lumakras, Imdelltra (Amg757) |
| Sumitomo Pharma America, INC. | $27.21 | 2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $26.85 | 2025 | |
| Tersera Therapeutics LLC | $25.23 | 2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $24.89 | 2025 | |
| Karyopharm Therapeutics INC. | $24.56 | 2025 | Xpovio |
| Ipsen Biopharmaceuticals, INC | $24.10 | 2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $23.89 | 2025 | |
| Kyowa Kirin, INC. | $22.84 | 2025 | |
| Legend Biotech USA INC. | $21.33 | 2025 | Carvykti |
| Genentech USA, INC. | $18.85 | 2025 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.92 | 2024 | Gilotrif |
| Sirtex Medical INC | $17.71 | 2025 | Sir-Spheres Microspheres |
| Caris Mpi, INC. | $17.60 | 2025 | Mi Cancer Seek |
| Beone Medicines USA, INC. | $16.84 | 2025 | Brukinsa |
| Azurity Pharmaceuticals, INC. | $16.59 | 2025 | Danziten |
| Taiho Oncology, INC. | $14.35 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.